United States Patent 8,932,610: Scope, Claim Construction, Exclusivity and Patent Landscape for Fluocinolone Acetonide Otic Compositions

U.S. Patent No. 8,932,610 protects sterile, preservative-free, clear aqueous otic solutions containing fluocinolone acetonide, with or without ciprofloxacin. The core commercial embodiment is a single-dose otic drop containing 0.025% fluocinolone acetonide and 0.3% ciprofloxacin, together with polysorbate 80, glycerin, povidone and water. The patent is directed primarily to formulation architecture rather than to fluocinolone acetonide or ciprofloxacin as chemical entities.

The patent presents a meaningful barrier to an identical or closely substituted generic formulation. Its strongest protection is concentrated in claim 1 and the narrower formulation of claim 8. Method claims 10-12 create additional risk for products promoted for the listed otic conditions, although method-of-use enforceability will depend on the approved label, induced-infringement evidence and the precise scope of any generic labeling.

What does U.S. Patent 8,932,610 cover?

The patent covers a sterile, preservative-free, clear aqueous otic formulation with six principal limitations:

Claim element	Scope
Active corticosteroid	0.01%-0.10% fluocinolone acetonide
Optional antibacterial	0.1%-0.8% ciprofloxacin or pharmaceutically acceptable salt
Surfactant	0.5%-4.0% polysorbate 80
Tonicity agent	0.5%-4.0% of one or more listed agents
Viscosity agent	0.05%-1.00% of one or more listed agents
pH	4.0-5.0, when pH adjustment is used
Vehicle	More than 90% water
Physical characteristics	Clear aqueous solution, substantially free from suspended particles
Solvent restriction	No non-aqueous solvents
Manufacturing and presentation	Sterilized; claim 9 narrows the product to disposable single-dose drop containers

The claim does not require ciprofloxacin. Claim 1 therefore covers both:

Fluocinolone acetonide-only otic solutions; and
Fluocinolone acetonide/ciprofloxacin combination solutions.

The optional language is commercially important. A formulation containing fluocinolone acetonide without ciprofloxacin may still fall within claim 1 if all other limitations are met.

How broad is claim 1 of U.S. Patent 8,932,610?

Claim 1 is a composition claim with multiple mandatory formulation limitations. Its breadth comes from the ranges and the alternative excipient groups. Its vulnerability comes from the requirement that all limitations be present in the claimed combination.

Active-ingredient range

The fluocinolone acetonide range is 0.01%-0.10% w/v. The commercial 0.025% strength is within the middle of the claimed range.

The optional ciprofloxacin range is 0.1%-0.8% w/v. A 0.3% ciprofloxacin formulation is also squarely within the claim.

A product containing 0.01% fluocinolone acetonide or 0.10% fluocinolone acetonide would remain within the literal range, subject to ordinary claim-construction rules. A formulation outside the stated range could still create an infringement issue under the doctrine of equivalents, but the range limitations would become a central litigation issue.

Polysorbate 80 range

The claim requires 0.5%-4.0% polysorbate 80. This is a material limitation, not a generic requirement for a surfactant. A formulation using polysorbate 20, poloxamer, lecithin or another surfactant instead of polysorbate 80 would not literally satisfy this element.

The use of 2%-3% polysorbate 80 in claim 8 narrows the broad range and aligns with the principal commercial formulation.

Tonicity-agent limitation

Claim 1 requires 0.5%-4.0% of one or more pharmaceutically acceptable tonicity agents. Claim 2 provides a closed list of examples, including glycerin, dextrose, sorbitol, mannitol and sodium chloride. Claim 3 narrows the tonicity agent to glycerin.

Claim 1 itself is broader than claim 2 because it does not expressly restrict the tonicity agent to the claim 2 list. A generic developer using a tonicity agent outside the claim 2 list may still face claim 1 exposure if the agent qualifies as pharmaceutically acceptable and satisfies the concentration and functional requirements.

Viscosity-agent limitation

The formulation must contain 0.05%-1.00% of one or more viscosity-increasing agents. Claim 4 lists numerous alternatives, including polyvinylpyrrolidone, polyvinyl alcohol, cellulose derivatives, gums, alginates, hyaluronic acid and carbomers.

Claims 5 and 6 focus on povidone, particularly Povidone K 90F. Claim 8 narrows the concentration to 0.1%-0.3% and specifies Povidone K 90F.

This limitation gives the patent practical reach over formulations that use viscosity adjustment to maintain the active ingredient in solution while avoiding suspended particles. It also creates a design-around opportunity if a competing formulation achieves acceptable otic residence time without a claimed viscosity-increasing agent.

Clear, particle-free aqueous solution

The requirement for a clear aqueous solution that is substantially free from particles in suspension distinguishes the claimed product from suspensions and particulate formulations.

A product marketed as a suspension would have a strong noninfringement position against this limitation, provided the product is genuinely a suspension and not merely a solution containing incidental particulate matter. Conversely, a nominally clear product containing crystallized active ingredient, visible particles or an intentionally dispersed solid phase could present claim-construction and factual disputes.

No non-aqueous solvents

Claim 1 excludes non-aqueous solvents. This limitation is significant for formulation design. Ethanol, propylene glycol and polyethylene glycol may create issues if used as solvents rather than as excipients serving another stated function.

The claim does not necessarily exclude every non-water ingredient. It expressly permits polysorbate 80, glycerin, povidone and pH-adjusting agents. The likely dispute would concern whether a particular ingredient is functioning as a non-aqueous solvent and whether the formulation is materially free of such solvents.

What formulations are protected by claims 2 through 9?

The dependent claims create a nested protection structure.

Claim	Narrowing feature
2	Specified tonicity-agent group
3	Glycerin as tonicity agent
4	Specified viscosity-agent group
5	Povidone K 25, K 30 or K 90F
6	Povidone K 90F
7	Specified pH-adjusting agents
8	0.02%-0.03% fluocinolone acetonide; 0.2%-0.4% ciprofloxacin; 2%-3% polysorbate 80; 2%-3% glycerin; 0.1%-0.3% Povidone K 90F
9	Sterilized disposable single-dose drop container

Claim 8 is the commercially significant fallback claim. It captures the formulation profile most closely associated with Otovel, including:

0.025% fluocinolone acetonide;
0.3% ciprofloxacin;
2%-3% polysorbate 80;
2%-3% glycerin;
0.1%-0.3% Povidone K 90F; and
water as the principal vehicle.

A generic matching these parameters would face cumulative exposure under claims 1, 3, 6, 8 and potentially 9.

What methods of treatment are protected by claims 10 through 12?

Claims 10-12 protect topical treatment or prevention of otic inflammation, with or without bacterial infection.

Claim 10 requires administration of a therapeutically effective amount of the composition of claim 1. It does not claim treatment with fluocinolone acetonide generally. The accused product must fall within the composition claim through its formulation and must be used in the claimed manner.

Claim 11 identifies inflammatory conditions such as:

Eczematoid external otitis;
Keloids;
Granular myringitis;
Bullous myringitis; and
Sudden deafness.

Claim 12 addresses inflammation accompanied by bacterial infection, including:

Diffuse and localized external otitis;
Traumatic tympanic membrane perforations;
Herpes zoster oticus;
Otitis media with effusion;
Otorrhea through tympanostomy tubes;
Acute otitis media with tympanostomy tubes;
Acute otitis media; and
Chronic suppurative otitis media.

The method claims are potentially narrower in litigation than their disease lists suggest. A generic applicant may seek a label that omits patented indications, although the effectiveness of a carve-out depends on whether the remaining label still encourages or necessarily results in the patented use. FDA labeling, promotional activity and physician-use evidence would be central to an induced-infringement analysis.

When does U.S. Patent 8,932,610 expire?

The patent has a nominal term based on its earliest claimed priority date in 2010. The expected base expiration is in August 2031, subject to any patent-term adjustment and the official expiration calculation recorded by the USPTO and FDA.

Event	Date or period
Earliest priority	August 2010
U.S. patent grant	January 13, 2015
Nominal 20-year term	August 2031
Regulatory exclusivity	Separate from patent term and substantially shorter
Orange Book relevance	Patent listing depends on the approved NDA and FDA listing status

Patent expiration should be confirmed against the USPTO Patent Center record and the current FDA Orange Book. Patent-term adjustment can move the expiration date beyond the base 20-year calculation. Patent-term extension under 35 U.S.C. § 156 would require a qualifying regulatory approval and an FDA-granted extension; the patent number alone does not establish such an extension.

What is the FDA and Orange Book status of the protected product?

The relevant commercial product is Otovel, an otic solution containing ciprofloxacin 0.3% and fluocinolone acetonide 0.025%. FDA approved Otovel under NDA 209673 in 2016. The product is a sterile, preservative-free single-dose otic solution administered as drops.

The FDA-approved product profile corresponds closely to claim 8. The commercial alignment increases the practical importance of the patent even though the patent claims are broader than the marketed strength.

Orange Book listing is relevant because an ANDA applicant must address listed patents through a paragraph I, II, III or IV certification. A paragraph IV certification alleging that the patent is invalid, unenforceable or not infringed can trigger patent litigation by the NDA holder or patent owner within the statutory period.

The approval of Otovel did not create new chemical entity exclusivity because fluocinolone acetonide and ciprofloxacin were previously known active ingredients. FDA regulatory exclusivity therefore does not replace the patent barrier. Any three-year exclusivity associated with new clinical investigations would have been materially shorter than the patent term and would not block entry after its expiration.

Are there Paragraph IV challenges or generic-entry risks?

The principal ANDA risk is a paragraph IV challenge directed to one or more of the following positions:

The accused formulation does not contain polysorbate 80 in the claimed range.
The product is a suspension rather than a clear solution.
The product contains a non-aqueous solvent and therefore does not meet the claim.
The viscosity agent is absent or outside the claimed concentration.
The formulation is outside the fluocinolone or ciprofloxacin ranges.
The patent claims are anticipated or obvious over earlier otic formulations.
The method claims are not infringed because the ANDA label omits the patented uses.
One or more claim terms are indefinite or lack adequate written-description support.

A generic matching the Otovel formulation has a high infringement exposure on the face of the claims. A materially different formulation could reduce risk, but the design-around must address the entire claim combination rather than only the active ingredients.

How strong is the patent estate?

The patent’s strength is strongest at the product-formulation level and weaker at the method-of-use level.

Issue	Assessment
Commercial-product overlap	High
Claim 8 relevance	High
Broad claim 1 reach	Moderate to high
Dependence on excipient selection	High
Risk from prior-art formulation patents	Material
Method-claim breadth	Moderate
Risk from label carve-out	Material
Biosimilar relevance	None
Manufacturing-process protection	Limited in the supplied claims

The patent does not claim a manufacturing process, sterilization cycle, filling process or container-closure system in general terms. Claim 9 protects the sterile single-dose presentation, but it does not create a comprehensive manufacturing barrier.

The patent also does not create biosimilar risk because Otovel is a small-molecule drug regulated through the ANDA pathway, not a biologic regulated under the Public Health Service Act. The relevant competitors are generic-drug manufacturers, not biosimilar developers.

How does the patent compare with competing otic products?

Otovel competes technically with other otic anti-infective and anti-inflammatory products, but those products do not necessarily implicate the same patent claims.

Product category	Typical active ingredients	Relationship to Patent 8,932,610
Otovel	Ciprofloxacin plus fluocinolone acetonide	Direct commercial target
Ciprodex	Ciprofloxacin plus dexamethasone	Different corticosteroid; generally outside fluocinolone limitation
Ciprofloxacin otic products	Ciprofloxacin alone	Outside the fluocinolone limitation
Steroid-only otic products	Hydrocortisone, dexamethasone or other steroid	Usually outside the fluocinolone limitation
Otic suspensions	Antibiotic and corticosteroid suspension	Potentially outside the clear-solution limitation
Compounded otic products	Variable	Risk depends on exact formulation and use

Ciprodex is not a direct formulation substitute for purposes of literal infringement because it uses dexamethasone rather than fluocinolone acetonide. Its own patent and regulatory history is separate.

What geographic coverage does the patent provide?

U.S. Patent 8,932,610 provides rights only in the United States and its territories. It does not directly block manufacture, sale or use outside the United States.

The underlying invention may have corresponding international applications or foreign national-phase patents. Foreign rights require separate review of each family member, prosecution history, claim scope, opposition status and expiration date. A U.S. freedom-to-operate conclusion cannot be extended to Europe, Canada, Japan, China or other markets without reviewing those jurisdictions independently.

What patent litigation and settlement issues matter?

A paragraph IV filing could result in a Hatch-Waxman action in federal district court. The central litigation issues would likely be infringement of claims 1 and 8, validity over prior-art aqueous otic solutions, and the effect of any label carve-out on method claims 10-12.

A settlement could establish a licensed generic launch date before patent expiration, subject to antitrust scrutiny and FDA approval. No launch date should be inferred solely from the patent’s expiration date. Commercial entry can occur earlier through:

A license from the patent owner or NDA holder;
A settlement with a permitted launch date;
A successful paragraph IV judgment;
A noninfringing formulation;
A regulatory pathway not blocked by the listed patent; or
Patent delisting or expiration.

Key Takeaways

U.S. Patent 8,932,610 is a formulation patent for sterile, preservative-free, clear aqueous fluocinolone acetonide otic solutions.
Claim 1 covers fluocinolone acetonide alone or in combination with ciprofloxacin.
Claim 8 is the principal commercial-risk claim because it closely tracks the Otovel formulation.
The key technical limitations are polysorbate 80, glycerin or another tonicity agent, a viscosity enhancer, water above 90%, pH 4.0-5.0, and the absence of non-aqueous solvents.
Claims 10-12 add method-of-use protection but are more vulnerable to label-carve-out and induced-infringement defenses.
The nominal patent term runs into August 2031, subject to official USPTO term calculations.
The relevant generic pathway is ANDA paragraph IV litigation, not biosimilar litigation.
Ciprodex and ciprofloxacin-only otic products are not direct literal substitutes for the claimed fluocinolone formulation.
A credible design-around would normally need to alter the formulation architecture, not merely change the active-ingredient strength.
Manufacturing-process protection is limited because the supplied claims focus on composition, use and single-dose presentation.

FAQs

Can a generic use ciprofloxacin and avoid U.S. Patent 8,932,610?

Yes, potentially. Ciprofloxacin alone does not satisfy the fluocinolone acetonide limitation. A combination product containing ciprofloxacin and another corticosteroid would require separate analysis.

Does using a different viscosity agent avoid the patent?

Not necessarily. Claim 1 broadly requires a pharmaceutically acceptable viscosity-increasing agent, while claim 4 identifies particular alternatives. Replacing Povidone K 90F may avoid claim 6 but still leave exposure under claim 1 or another dependent claim.

Does a suspension avoid the patent?

A genuine suspension has a strong argument against the clear aqueous solution and particle-free limitations. The product’s actual physical state, labeling and manufacturing specifications would control.

Can a generic launch before August 2031?

Yes, if it obtains a license, prevails in paragraph IV litigation, uses a noninfringing formulation, relies on an effective label carve-out, or benefits from another legally available entry route.

Is Otovel subject to biosimilar competition?

No. Otovel is a small-molecule drug. Competition proceeds through the generic-drug ANDA system rather than the biosimilar pathway.

References

U.S. Patent and Trademark Office. (2015). U.S. Patent No. 8,932,610, Otic pharmaceutical compositions.
U.S. Food and Drug Administration. (2016). Otovel (ciprofloxacin and fluocinolone acetonide) otic solution prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Otovel, NDA 209673.
21 U.S.C. § 355. Abbreviated applications and patent certifications.
35 U.S.C. §§ 154, 156. Patent term and patent-term extension.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lab Salvat	OTOVEL	ciprofloxacin hydrochloride; fluocinolone acetonide	SOLUTION/DROPS;OTIC	208251-001	Apr 29, 2016		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF ACUTE OTITIS MEDIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	10155005	Mar 1, 2010

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	080368	⤷ Start Trial
Australia	2011223095	⤷ Start Trial
Brazil	112012021638	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,932,610

Which drugs does patent 8,932,610 protect, and when does it expire?

Summary for Patent: 8,932,610